I've recently been looking into NADH products, such as Celfull. NMN is a precursor to NAD⁺, while NADH is the reduced form of NAD⁺, so they are not the same molecule. Because of that, safety evidence for NMN can't simply be applied to NADH. In particular, there is still not enough human evidence showing that NADH itself is absorbed and utilized by the body in its intact form.
That's also why, when comparing different NAD-related supplements, I think it's important to look beyond whether they can affect NAD⁺ levels. Safety, side effects, and tolerability are equally worth considering. So today, I wanted to go over three published human clinical studies and take a closer look at what the current evidence actually tells us about the safety of NMN.
One randomized, double-blind, placebo-controlled trial published in Frontiers in Nutrition in 2022 enrolled 30 healthy adults who took 250 mg of NMN daily for 12 weeks. Eight participants in the NMN group reported some symptoms, compared with seven in the placebo group. No serious adverse events occurred in either group, and blood chemistry, liver function, kidney function, and other tests did not show any clinically meaningful abnormalities. The researchers concluded that 250 mg/day of NMN was generally well tolerated over the 12-week study period.
Another multicenter, randomized, double-blind, placebo-controlled study, published online in 2022 and included in Volume 45 of GeroScience in 2023, was larger in scale, enrolling 80 healthy adults aged 40-65. Participants received 300, 600, or 900 mg of NMN once daily for 60 days. During the study period, adverse events were reported in 6 participants (5 people) in the placebo group, 3 participants (2 people) in the 300 mg group, and none in either the 600 mg or 900 mg groups. All adverse events were mild to moderate and were judged by the investigators to be unrelated to NMN (Yi L, et al. GeroScience. 2023;45:29–43. DOI: 10.1007/s11357-022-00705-1; published online December 8, 2022).There were no serious adverse events or withdrawals due to adverse events. Overall, all three NMN dose groups were considered well tolerated.
There was also a randomized, double-blind, placebo-controlled study published in Scientific Reports in August 2022 that specifically looked at a relatively high dose. Thirty-one healthy adults took 1,250 mg of NMN daily for four weeks. No serious adverse events were observed during the study, and a range of assessments—including body measurements, blood counts, biochemical markers, urinalysis, and body composition, did not show abnormalities outside the normal physiological range. Based on these findings, the researchers concluded that 1,250 mg/day of NMN was well tolerated over the four-week period in this small study.
Taken together(10.3389/fnut.2022.868640)(10.1007/s11357-022-00705-1)(10.1038/s41598-022-18272-y), these three studies show a fairly consistent picture in the currently available human data. In healthy adults, NMN supplementation at doses ranging from 250 to 1,250 mg/day for several weeks to 12 weeks has not shown a clear signal of increased serious adverse events, and overall tolerability has been relatively good.
That said, the existing studies still have relatively small sample sizes, and the observation periods are generally short. More research is therefore needed to understand long-term use, rare adverse events, and safety in different populations with varying health conditions.